SAT0206 Results of the alterra clinical trial – the efficacy of the alternative dosing regimen for rituximab biosimilar in bdmards naive patients with rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2300
Abstract: Background: Rituximab (RTX) is successfully used in patients with active rheumatoid arthritis (RA) who previously received biological disease-modifying antirheumatic drugs (bDMARDs) at a dose of 1000 mg. Previous preclinical and clinical studies showed that BCD-020… read more here.
Keywords: none declared; naive patients; bcd 020; arm ... See more keywords